RMDN3 and breast cancer: Thus, the LDC3/Dynarrestin altered the phosphorylation of the Tyr176 residue and the recruitment of PTPIP51 into MAPK signaling are based on the same modulations both in the breast cancer cell as well as in the physiological system of the HaCaT cell.